BSG and neoplasm: Aberrant glycosylation also exhibits definite effects on specific cellular functions, serving as a biomarker in multiple tumor types: aberrant glycosylation of cancer antigen (CA)125 leads to cancer progression, CD43 contributes to metastasis, CA19-9 contributes to tumor recurrence, and CD147 contributes to drug resistance (2–5).